- Home
- JBLU vs PTGX Comparison
JBLU vs PTGX Comparison
Compare JBLU & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBLU | PTGX |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 5.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | JBLU | PTGX |
|---|---|---|
| Price | $4.73 | $88.83 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $4.76 | ★ $90.56 |
| AVG Volume (30 Days) | ★ 17.3M | 1.1M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | ★ $9,095,000,000.00 | $209,217,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.18 | $296.47 |
| P/E Ratio | ★ N/A | $123.20 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.34 | $33.70 |
| 52 Week High | $8.31 | $96.54 |
Technical Indicators
Market Signals| Indicator | JBLU | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 51.60 | 53.99 |
| Support Level | $4.72 | $84.11 |
| Resistance Level | $4.99 | $90.00 |
| Average True Range (ATR) | 0.22 | 3.31 |
| MACD | -0.02 | -0.75 |
| Stochastic Oscillator | 24.07 | 38.05 |
Price Performance
Historical ComparisonAbout JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.